TLR9-based immunotherapy for the treatment of allergic diseases. (March 2017)

• Record Type: Journal Article
• Authors: Farrokhi, Shokrollah; Abbasirad, Narjes; Movahed, Ali; Khazaei, Hossein Ali; Pishjoo, Masoud; Rezaei, Nima
• Is Part Of: Immunotherapy. Volume 9:Number 4(2017)
• Page Start: 339
• Page End: 346
• Publication Date: 2017-03
• Subjects: allergic diseases -- immunotherapy -- TLR9 -- Toll-like receptors; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2016-0104
• Languages: English
• ISSNs: 1750-743X

Abstract

Toll-like receptors (TLRs), a family of pattern recognition receptors expressed on many cell types of innate immunity, recognize the pathogen-associated molecular patterns of microbes. The hygiene hypothesis suggests that a reduced microbial exposure in early childhood increases the susceptibility to allergic diseases due to deviation in development of the immune system. TLRs are key roles in the right and healthy direction of adaptive immunity with the induction of T-helper 2 toward Th1 immune responses and regulatory T cells. TLR ligand CpG-ODN-based immunomodulation is independent of allergen and it mainly affects innate immune system. While, CpG-oligodeoxynucleotide-based vaccination is allergen specific and induces adaptive immune system. The use of agonists of TLR9 in two distinct strategies of immunotherapy, immunomodulation and vaccination, could be presented as the curative method for the treatment of allergic diseases.